An Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Volasertib (BI 6727) in Combination with Decitabine in Patients with Acute Myeloid Leukemia
What is the purpose of this trial?
The primary objective is to investigate the maximum tolerated dose (MTD), safety and efficacy of volasertib in combination with decitabine in patients with acute myeloid leukaemia (AML).
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Last Updated:
- Study HIC#: